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Abstract
Background
Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention 
of human immunodeficiency virus (HIV) infection in some trials but not in others.
Methods
In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-
negative women in Kenya, South Africa, and Tanzania to receive either a combina-
tion of tenofovir disoproxil fumarate and emtricitabine (TDF–FTC) or placebo once 
daily. The primary objective was to assess the effectiveness of TDF–FTC in prevent-
ing HIV acquisition and to evaluate safety.
Results
HIV infections occurred in 33 women in the TDF–FTC group (incidence rate, 4.7 per 
100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-
years), for an estimated hazard ratio in the TDF-FTC group of 0.94 (95% confidence 
interval, 0.59 to 1.52; P = 0.81). The proportions of women with nausea, vomiting, or 
elevated alanine aminotransferase levels were significantly higher in the TDF–FTC 
group (P = 0.04, P<0.001, and P = 0.03, respectively). Rates of drug discontinuation 
because of hepatic or renal abnormalities were higher in the TDF–FTC group (4.7%) 
than in the placebo group (3.0%, P = 0.051). Less than 40% of the HIV-uninfected 
women in the TDF–FTC group had evidence of recent pill use at visits that were 
matched to the HIV-infection window for women with seroconversion. The study 
was stopped early, on April 18, 2011, because of lack of efficacy.
Conclusions
Prophylaxis with TDF–FTC did not significantly reduce the rate of HIV infection and 
was associated with increased rates of side effects, as compared with placebo. Despite 
substantial counseling efforts, drug adherence appeared to be low. (Supported by the 
U.S. Agency for International Development and others; FEM-PrEP ClinicalTrials.gov 
number, NCT00625404.)
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Recent studies have shown that daily oral preexposure prophylaxis with 300 mg of tenofovir disoproxil fumarate 
(TDF), an oral prodrug of tenofovir, alone or in 
combination with 200 mg of emtricitabine (FTC) 
(TDF–FTC [Truvada], Gilead Sciences) can reduce 
the risk of sexually acquired human immunodefi-
ciency virus (HIV) infection in men and women.1-3 
Consequently, an advisory committee of the Food 
and Drug Administration recently recommended 
that the label indications for Truvada be changed 
to include HIV prevention.4
We report the primary results of the Preexpo-
sure Prophylaxis Trial for HIV Prevention among 
African Women (FEM-PrEP), a randomized, double-
blind, placebo-controlled trial of once-daily oral 
TDF–FTC among high-risk women in Africa. The 
study was stopped early, on April 18, 2011, be-
cause of a lack of efficacy.
Methods
Participants
From June 11, 2009, to April 15, 2011, we re-
cruited women at four study centers in Kenya, 
South Africa, and Tanzania. To be eligible, wom-
en in good health who were between the ages of 
18 and 35 years had to test negative for HIV anti-
body, be at increased risk for HIV infection, not be 
pregnant or breast-feeding, be willing to use an 
effective nonbarrier contraceptive method, show 
an ability to swallow a vitamin tablet similar in 
size to that of a study tablet, and pass an in-
formed-consent quiz. Women were considered to 
be at increased risk for HIV infection if they had 
had one or more vaginal sex acts in the previous 
2 weeks or more than one sex partner in the pre-
vious month. Women were excluded if they tested 
positive for the hepatitis B virus surface antigen 
or had evidence of abnormal hepatic or renal 
function. (Details are provided in the study pro-
tocol, available with the full text of this article at 
NEJM.org.) At most sites, the Priorities for Local 
AIDS Control Efforts (PLACE) method was adapt-
ed to identify geographic areas of high risk and 
prioritize these regions for recruitment efforts.5 
All women provided written informed consent.
Extensive sociobehavioral research and com-
munity activities were part of the trial and in-
formed several trial procedures, including recruit-
ment, retention, informed consent, and adherence 
counseling. The trial was approved by all appli-
cable ethics and regulatory committees.
Visit Procedures
Participants attended clinic visits at the time of 
screening and enrollment and at 4-week intervals 
thereafter for up to 60 weeks (52 weeks of taking 
the study drug, followed by 8 weeks off the study 
drug). At each visit, participants received a month’s 
supply of the assigned study drug; underwent 
rapid HIV antibody testing, pregnancy testing, 
and assessment for adverse events; and received 
counseling (with respect to risk reduction, study-
drug adherence, and contraceptive use), free con-
doms, and free (or referral for) effective nonbarrier 
contraception. In addition, self-reported adher-
ence was assessed, returned pills were counted, 
and blood samples were obtained and stored. At 
predefined visits, testing of hepatic and renal 
function was performed, and a questionnaire on 
sexual behavior was administered. The adminis-
tration of the study drug was temporarily or per-
manently discontinued in case of pregnancy, sero-
conversion to HIV positivity, or protocol-defined 
biochemical abnormalities.
Objectives and End Points
The primary objective was to assess the effective-
ness and safety of TDF–FTC in preventing HIV 
acquisition. The secondary objectives reported 
here include assessing the effect of TDF–FTC on 
the CD4+ T-cell count and plasma HIV RNA level 
(viral load), the rate of HIV infection with resistance 
to TDF–FTC, changes in risk behavior, adherence 
to the study regimen, and effects on pregnancy 
outcomes.
The primary effectiveness end point was inci-
dent infection with HIV type 1 (HIV-1) or type 2 
(HIV-2), as determined by the presence of anti-
bodies on two consecutive rapid tests conducted 
on plasma. Primary safety end points included 
grade 3 or higher elevations in the alanine amino-
transferase or aspartate aminotransferase level, 
grade 3 or higher reductions in phosphorus, and 
grade 2 or higher elevations in the creatinine level; 
assessments were based on the grading table of 
the Division of AIDS and on local normal ranges.6 
HIV-1 resistance was determined with the use of 
genotypic testing (TRUGENE, Siemens) and phe-
notypic testing (PhenoSense, Monogram Biosci-
ences).
Drug-Level Analysis
We measured levels of tenofovir and FTC in plas-
ma samples, using protein precipitation and liquid 
chromatography with tandem mass spectrometry 
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detection with deuterated internal standards. The 
lower limit of quantification was 0.25 ng per mil-
liliter. Rates of intraassay and interassay accuracy 
ranged from 96 to 112%, and rates of intraassay 
and interassay precision ranged from 5 to 13%.
Study Oversight
The trial was supported by a grant from the 
Agency for International Development and by the 
Bill and Melinda Gates Foundation for commu-
nity preparatory work in some sites. The study 
2120 Underwent randomization
63 in Arusha
739 in Bondo
554 in Bloemfontein
764 in Pretoria
4163 Women were assessed for eligibility
211 in Arusha
1725 in Bondo
921 in Bloemfontein
1306 in Pretoria
2043 Were excluded
18 Did not pass informed-consent quiz
845 Were HIV-positive at screening
or enrollment
149 Were pregnant
8 Were HIV-positive and pregnant
323 Did not return for enrollment
424 Had medical conditions
18 Declined contraception
68 Did not meet risk criteria
59 Were breast-feeding
51 Were not enrolled owing to study
closure
80 Had other reasons
1062 Were assigned to receive TDF–FTC 1058 Were assigned to receive placebo
38 Were excluded
1 Was HIV-positive
at enrollment
37 Did not undergo 
follow-up test
26 Were excluded
1 Was HIV-positive
at enrollment
25 Did not undergo 
follow-up test
148 (13.9%) Were lost to follow-up
59 (5.6%) Discontinued early
855 (80.5%) Completed study
118 (11.2%) Were lost to follow-up
54 (5.1%) Discontinued early
886 (83.7%) Completed study
1024 Were evaluated for effectiveness 
(701.5 person-yr of follow-up)
29 (4.6 person-yr) in Arusha
356 (297.1 person-yr) in Bondo
261 (116.1 person-yr) in Bloemfontein
378 (283.6 person-yr) in Pretoria
1032 Were evaluated for effectiveness
(705.9 person-yr of follow-up)
28 (5.0 person-yr) in Arusha
364 (298.1 person-yr) in Bondo
268 (119.4 person-yr) in Bloemfontein
372 (283.4 person-yr) in Pretoria
Figure 1. Screening, Randomization, and Follow-up of the Study Participants.
The percentages of participants who completed the study and were included in the primary analysis were calculated 
on the basis of the total numbers of participants in the two randomized study groups. HIV infection at the time of 
enrollment was further determined by subsequent polymerase-chain-reaction assay.
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was designed and the protocol written by the two 
principal investigators and lead statistician in 
collaboration with the other investigators and in-
put from an external protocol advisory committee. 
Gilead Sciences donated the study drugs (TDF–
FTC and placebo) and was allowed to review the 
draft manuscript and provide comments but had 
no other role in the trial. The data were analyzed 
by the last author. The first and last authors, 
along with the data-management group, vouch for 
the accuracy and completeness of the data and 
the fidelity of this report to the study protocol.
Statistical Analysis
The study was designed to test the hypothesis that 
once-daily TDF–FTC is more than 30% effective 
in preventing HIV acquisition. An enrollment of 
3900 women was expected to provide the 72 infec-
tions required to achieve a power of 90% on the 
basis of a one-sided alpha level of 0.025, an as-
sumed cumulative probability of infection at 1 year 
of 3% in the placebo group, and an assumed rela-
tive reduction in risk of 70%.
The primary effectiveness analysis was based 
on a confidence interval for the hazard ratio for 
infection in the TDF–FTC group, as compared 
with the placebo group, that was obtained from 
a proportional-hazards regression model stratified 
according to study site. This analysis excluded 
women who were subsequently determined to 
have been infected with HIV at enrollment on the 
basis of polymerase-chain-reaction assay and those 
who did not undergo HIV follow-up testing. We 
determined the coverage error of the confidence 
interval that was reported at each interim analysis 
by using the Lan–DeMets spending function with 
Table 1. Baseline Characteristics of the Participants.*
Characteristic
TDF–FTC  
(N = 1062)
Placebo  
(N = 1058)
All Participants  
(N = 2120)
Study site — no. (%)
Arusha, Tanzania† 33 (3.1) 30 (2.8) 63 (3.0)
Bloemfontein, South Africa 276 (26.0) 278 (26.3) 554 (26.1)
Bondo, Kenya 370 (34.8) 369 (34.9) 739 (34.9)
Pretoria, South Africa 383 (36.1) 381 (36.0) 764 (36.0)
Age — yr
Mean 24.2 24.2 24.2
Median (range) 23 (18–35) 23 (18–35) 23 (18–35)
Education — yr
Mean 10.4 10.3 10.3
Median (range) 11 (0–19) 11 (0–19) 11 (0–19)
Married — no. (%) 319 (30.0) 336 (31.8) 655 (30.9)
Ever pregnant — no. (%) 755 (71.1) 778 (73.5) 1533 (72.3)
Contraceptive method at screening — no. (%)
Oral pills 101 (9.5) 75 (7.1) 176 (8.3)
Injectable contraceptives 404 (38.0) 410 (38.8) 814 (38.4)
Condoms 170 (16.0) 175 (16.5) 345 (16.3)
Implant, IUD, or female sterilization 27 (2.5) 26 (2.5) 53 (2.5)
Other 4 (0.4) 2 (0.2) 6 (0.3)
None 356 (33.5) 370 (35.0) 726 (34.2)
Contraceptive method at enrollment — no. (%)
Oral pills 340 (32.0) 298 (28.2) 638 (30.1)
Injectable contraceptives 675 (63.6) 726 (68.6) 1401 (66.1)
Implant, IUD, or female sterilization 47 (4.4) 34 (3.2) 81 (3.8)
Has primary partner — no. (%) 1051 (99.0) 1043 (98.6) 2094 (98.8)
Has other, nonprimary partners — no. (%) 286 (26.9) 270 (25.5) 556 (26.2)
Sex for money or gifts with a nonprimary partner in previous  
4 wk — no. (%)
139 (13.1) 129 (12.2) 268 (12.6)
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O’Brien–Fleming–type boundaries in EAST soft-
ware (Cytel).7 Since the trial was stopped because 
of futility, unadjusted two-sided 95% confidence 
intervals and P values are reported here.
Primary safety analyses, which excluded wom-
en for whom no follow-up safety data were avail-
able and those who returned all their pills unused, 
were based on exact log-rank tests of between-
group differences in the rates of grade 3 or higher 
alanine aminotransferase, aspartate aminotrans-
ferase, and phosphorus levels and grade 2 or 
higher creatinine levels.
We also conducted a nested case–control 
analysis using data on plasma drug levels. In the 
TDF–FTC group, for every participant with sero-
conversion to HIV positivity, we matched three 
participants without HIV infection (controls), ac-
cording to the study site and the duration of par-
ticipation in the study.
Results
Recruitment and Follow-up
During the nearly 2-year recruitment period, 4163 
women were screened and 2120 underwent ran-
domization (Fig. 1). Demographic characteristics 
and other baseline data were generally similar in 
the two groups (Table 1). The mean age was 24.2 
years. Among the women who were tested at base-
line, 5.7% had gonorrhea and 14.0% had chla-
mydial infection; 41.8% had bacterial vaginosis. 
Participants reported an average of 3.7 vaginal sex 
acts, 1.9 sex acts without a condom, and 1.0 sex 
partners in the 7 days before enrollment; 12.6% 
reported exchanging sex for money or gifts with 
a nonprimary partner in the previous 4 weeks. At 
enrollment, most participants were using an in-
jectable contraceptive (66.1%) or oral contraceptive 
(30.1%) to meet the study requirement, with more 
use of oral contraceptives in the TDF–FTC group 
than in the placebo group (32.0% vs. 28.2%).
Among enrolled participants, 62 (2.9%) had 
no follow-up HIV testing; it was determined that 
2 participants (1 in each study group) had preex-
isting HIV infection, leaving 2056 women who 
contributed 1407.4 person-years to the primary ef-
fectiveness analysis (Fig. 1). A total of 266 women 
(12.5%) were lost to follow-up, with a determina-
tion that a third of these women had relocated 
without returning for a final visit. Another 113 
women (5.3%) discontinued the study early (most 
for personal reasons unrelated to the study), 
Table 1. (Continued.)
Characteristic
TDF–FTC  
(N = 1062)
Placebo  
(N = 1058)
All Participants  
(N = 2120)
Partners in past wk — no.
Mean 1.0 1.0 1.0
Median (range) 1 (0–6) 1 (0–11) 1.0 (0–11)
Vaginal sex acts in past wk — no.
Mean 3.7 3.7 3.7
Median (range) 3 (0–28) 3 (0–23) 3 (0–28)
Sex without a condom in past wk — no.
Mean 1.9 1.9 1.9
Median (range) 1 (0–25) 1 (0–23) 1 (0–25)
Anal sex in past 4 wk — no. (%) 14 (1.3) 14 (1.3) 28 (1.3)
Diagnosis of sexually transmitted infection — no./total no. (%)
Gonorrhea 56/939 (6.0) 52/948 (5.5) 108/1887 (5.7)
Chlamydial infection 142/939 (15.1) 122/948 (12.9) 264/1887 (14.0)
Trichomoniasis 64/943 (6.8) 45/950 (4.7) 109/1893 (5.8)
Syphilis 21/1060 (2.0) 15/1058 (1.4) 36/2118 (1.7)
Bacterial vaginosis 402/932 (43.1) 383/945 (40.5) 785/1877 (41.8)
Positive for hepatitis B surface antibody 220/1060 (20.8) 226/1056 (21.4) 446/2116 (21.1)
* There were no significant differences between the two study groups, except for the contraceptive method used at enroll-
ment (P = 0.04). IUD denotes intrauterine device.
† In Arusha, the trial was initiated in November 2010, a few months before the unexpected closure.
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leaving 1741 of 2120 women (82.1%) who con-
tracted HIV infection or completed follow-up and 
were included in the primary end-point analysis.
Effectiveness
Of the 68 HIV infections that occurred before the 
visit at 52 weeks (or the first visit after April 18, 
2011), 33 occurred in the TDF–FTC group (inci-
dence rate, 4.7 per 100 person-years) and 35 in 
the placebo group (incidence rate, 5.0 per 100 
person-years), leading to an estimated hazard ra-
tio in the TDF–FTC group of 0.94 (95% confidence 
interval [CI], 0.59 to 1.52; P = 0.81) (Table 2). A 
prespecified sensitivity analysis in which data 
were censored when the study drug was no longer 
available (i.e., owing to an interruption or a missed 
visit) also showed a between-group difference 
that was not significant (hazard ratio, 0.82; 95% 
CI, 0.49 to 1.36; P = 0.44). When all HIV infec-
tions occurring after randomization (i.e., through 
week 8 after the regular study visit) were includ-
ed in the analysis, there were 34 infections in the 
TDF–FTC group and 39 in the placebo group 
(hazard ratio, 0.87; 95% CI, 0.55 to 1.38; P = 0.56). 
The estimated cumulative probability of infec-
tion at 12 months was 0.049 in the TDF–FTC 
group and 0.046 in the placebo group (Fig. 2).
Safety
Less than 1% of women had grade 3 or higher he-
patic abnormalities or grade 2 or higher creatinine 
abnormalities, with no significant differences 
between the two study groups (Table 3). Rates of 
grade 3 or higher phosphorus abnormalities 
were also similar in the two groups (4.4% in the 
TDF–FTC group and 3.9% in the placebo group, 
P = 0.59). With respect to other prespecified safe-
ty end points, only the proportions of women with 
nausea (P = 0.04), vomiting (P<0.001), and any ala-
nine aminotransferase elevation (P = 0.03) were 
significantly higher in the TDF–FTC group, with 
rates of vomiting and nausea more frequent in 
the first few months of follow-up. (Details re-
garding the safety analysis are provided in the 
Supplementary Appendix, available at NEJM.org.)
Less than 5% of women had hepatic or renal 
abnormalities requiring discontinuation of the 
study drug (Table S4 in the Supplementary Appen-
dix), with a trend toward a significant between-
group difference (4.7% in the TDF–FTC group vs. 
3.0% in the placebo group, P = 0.051).
There were 36 serious adverse events reported U
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in the TDF–FTC group and 24 in the placebo 
group. (A complete list is provided in Table S2 in 
the Supplementary Appendix.) One participant 
in the TDF–FTC group was hospitalized with 
diarrhea and severe dehydration and later died. 
Another participant in the placebo group died of 
unknown causes several months after her last 
clinic visit. We were unable to obtain any addi-
tional details with respect to these two events. 
The percentage of women with pregnancy-
related adverse events was higher in the TDF–FTC 
group (P = 0.04), but there were also 74 pregnan-
cies in this group (incidence rate, 11.2 per 100 
person-years), as compared with 51 in the pla-
cebo group (incidence rate, 7.5 per 100 person-
years). In a preliminary analysis, there was no 
evidence of a difference between groups in rates 
of abortions or other potentially teratogenic ef-
fects. The between-group difference in pregnancy 
rates was not significant after adjustment for 
study site, age, and the imbalance in the use of 
oral contraceptives at baseline (hazard ratio, 1.32; 
P = 0.13). Pregnancy rates were highest among par-
ticipants who chose to use oral contraceptives at 
baseline (incidence rate, 29.0 per 100 person-years), 
with no significant difference between the two 
study groups.
Among participants in whom HIV infection was 
identified, there was no significant between-
group difference in the mean CD4+ counts or 
log10 viral loads (Table 3). We did not observe 
any K65R or K70E mutations in reverse tran-
scriptase, which cause resistance to tenofovir. 
Among women with HIV seroconversion, one in 
the placebo group and three in the TDF–FTC 
group were infected with a viral strain with a 
M184V mutation in reverse transcriptase; a fourth 
woman with a resistant infection in the TDF–FTC 
group had a viral strain with an M184I muta-
tion. Both M184V and M184I mutations cause 
resistance to FTC. Phenotypic testing was suc-
cessful in four of the five resistant infections and 
confirmed resistance to FTC.
Adherence
At the time of study-drug discontinuation, 95% 
of participants reported that they had usually or 
always taken the assigned drug. Pill-count data 
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Figure 2. Kaplan–Meier Estimates of the Cumulative Probability of HIV Infection.
Shown are the numbers of participants who were at risk at the start of each 4-week interval. The estimated cumulative 
probability of HIV infection at 12 months was 0.049 in the TDF–FTC group and 0.046 in the placebo group.
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were consistent with ingestion of the study drug 
on 88% of the days on which it was available to 
the participants. In contrast, drug-level testing re-
vealed much lower levels of adherence. In prespec-
ified analyses, we considered that 10 ng of teno-
fovir per milliliter in plasma was evidence that TDF 
had been taken within the previous 48 hours.8 
Among women with seroconversion in the TDF–
FTC group, the target plasma level of tenofovir 
(≥10 ng per milliliter) was identified in 7 of 27 
women (26%) at the beginning of the infection 
window (excluding 6 women for whom the win-
dow started at enrollment), in 7 of 33 (21%) at the 
end of the window, and in 4 of 27 (15%) at both 
visits (Fig. S2 in the Supplementary Appendix).
Among the uninfected control participants, the 
numbers of women with target-level tenofovir 
were somewhat higher: 27 of 78 women (35%) at 
the beginning of the infection window, 35 of 95 
(37%) at the end of the window, and 19 of 78 
(24%) at both visits. These differences were not 
significant after adjustment for age, unprotected 
sex, and use of injectable contraception (P = 0.70 
at the start of the infection window, P = 0.13 at 
end of the window, and P = 0.68 at both visits).
Risk Perception and Sexual Behavior
Most women perceived themselves to be at no or 
low risk for HIV infection in the coming month 
when asked at the baseline visit (70.0%) and at 
the last regular follow-up visit (74.8%). There was 
no evidence of increased HIV risk behavior dur-
ing the trial, with modest but significant reduc-
tions in the numbers of partners (mean reduc-
tion, 0.14; P<0.001 by paired-data t-test), vaginal 
sex acts (mean reduction, 0.58; P<0.001), and sex 
acts without a condom (mean reduction, 0.46; 
P<0.001) reported by women at the last follow-up 
visit, as compared with 7 days before enrollment.
Fewer than half the study participants agreed to 
undergo a pelvic examination after randomization, 
so we were not able to confirm the self-reported 
data on risk behavior on the basis of data regard-
ing sexually transmitted infections. Among par-
ticipants who underwent testing at the final visit, 
there were no significant between-group differ-
ences in the prevalence of trichomoniasis (3.5% 
in the TDF–FTC group and 5.8% in the placebo 
group, P = 0.20), candidiasis (15.2% and 15.2%, 
respectively; P = 1.00), gonorrhea (4.9% and 3.2%, 
P = 0.25), or chlamydial infection (13.3% and 
12.0%, P = 0.65).
Discussion
In this study, there was no significant reduction 
in HIV acquisition among women in the TDF–FTC 
group, as compared with the placebo group. Drug-
level analyses revealed that less than 40% of the 
HIV-uninfected women had evidence of recent 
pill use at visits that were matched to the HIV-
infection window for women with seroconver-
sion. If such low adherence levels prevailed for 
the entire cohort, the trial was substantially un-
derpowered to detect an effect of TDF–FTC on 
the risk of HIV acquisition. Although women in the 
TDF–FTC group had higher rates of some known 
side effects than those in the placebo group, the 
prevalence of these events was modest and con-
sistent with the overall low adherence. However, 
the rate of adverse events might have been higher 
if the level of adherence had been higher.
Relatively low adherence levels were also ob-
served in the case–control analysis in the Preex-
posure Prophylaxis Initiative study involving men 
who have sex with men,9 in which tenofovir was 
detected in 44% of the uninfected controls. This 
finding might indicate that TDF–FTC is more 
forgiving of imperfect use with rectal exposure to 
HIV than with vaginal exposure, possibly because 
of a difference in concentrations of the active me-
tabolites in rectal and vaginal tissues after oral 
administration.10
In the Partners Preexposure Prophylaxis 
study,2,11 there was a highly significant protective 
effect of both TDF and TDF–FTC in the overall 
study population and among female participants. 
Among uninfected controls, drug-level analyses 
revealed adherence rates of 81% in the TDF–FTC 
group and 83% in the TDF group. Thus, if there 
are biologic differences between drug responses 
in men and those in women or between HIV ex-
posure with vaginal and rectal sex, it appears that 
these differences may be overcome with high rates 
of adherence.
In the Vaginal and Oral Interventions to Control 
the Epidemic (VOICE, or MTN-003) trial among 
women,12 treatment with daily oral TDF was 
stopped early because of a lack of effectiveness, a 
finding that is similar to ours for TDF–FTC and 
that contrasts with the findings for both TDF and 
TDF–FTC in the Partners Preexposure Prophylaxis 
study. One of the hypotheses is that low adherence 
may have played a role. In the VOICE trial, partici-
pants continue to receive daily oral TDF–FTC.
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It is important to understand why so many 
women came for the monthly visits and under-
went frequent blood testing but did not take their 
pills. We hypothesize that the women’s percep-
tion that they were at low risk for HIV infection 
may have contributed to the poor adherence. In 
addition, the high pregnancy rate among women 
receiving oral contraceptives may indicate diffi-
culty with daily pill regimens. Understanding 
these issues and identifying characteristics pre-
dictive of high adherence will be important in 
developing strategies for adherence counseling 
for future studies and programs.
Self-reported behaviors and data regarding the 
prevalence of sexually transmitted infections do 
not suggest increased risk behavior among wom-
en in the TDF–FTC group. Although there were 
slightly higher rates of study-drug discontinuation 
owing to adverse events in the TDF–FTC group, 
the percentage of days on which women had a 
study drug available for use was high in the two 
groups.
There were no major safety concerns in the 
trial, although low adherence may have compro-
mised our ability to identify a safety concern or an 
effect on the CD4+ T-cell count and viral load in 
Table 3. Safety Outcomes.*
Variable TDF–FTC (N = 1025) Placebo (N = 1033) P Value†
no. of participants 
(%) no. of events
no. of participants 
(%) no. of events
Any adverse event 760 (74.1) 2373 747 (72.3) 2247 0.37
Nausea 50 (4.9) 52 32 (3.1) 33 0.04
Vomiting 37 (3.6) 38 12 (1.2) 12 <0.001
Diarrhea 17 (1.7) 18 17 (1.6) 21 1.00
Fatigue 17 (1.7) 17 8 (0.8) 8 0.07
Respiratory tract infection 96 (9.4) 108 108 (10.5) 125 0.42
Nasopharyngitis 19 (1.9) 21 36 (3.5) 42 0.03
Fracture 1 (0.1) 1 2 (0.2) 2 1.00
Intentional overdose 2 (0.2) 2 2 (0.2) 2 1.00
Depression 0 0 1 (0.1) 1 1.00
Other important adverse events
Genital ulceration 10 (1.0) 10 1 (0.1) 2 0.006
Any pregnancy-related event 24 (2.3) 28 12 (1.2) 12 0.04
Any serious adverse event‡ 33 (3.2) 36 23 (2.2) 24 0.18
Laboratory abnormality leading to study-drug interruption 
or permanent discontinuation
48 (4.7) 74 31 (3.0) 35 0.05
Laboratory abnormality
Elevated ALT
≥Grade 1 117 (11.4) 153 89 (8.6) 100 0.03
≥Grade 3§ 6 (0.6) 6 8 (0.8) 8 0.79
Elevated AST
≥Grade 1 180 (17.6) 229 153 (14.8) 188 0.09
≥Grade 3§ 3 (0.3) 3 1 (0.1) 1 0.62
Elevated creatinine
≥Grade 1 68 (6.6) 89 54 (5.2) 69 0.19
≥Grade 2§ 4 (0.4) 4 2 (0.2) 2 0.45
Decreased phosphorus
≥Grade 2 201 (19.6) 253 195 (18.9) 258 0.65
≥Grade 3§ 45 (4.4) 50 40 (3.9) 43 0.59
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participants with seroconversion. Five participants 
had HIV infections that were resistant to FTC, 
one of them in the placebo group. Among these 
five participants, one in the TDF–FTC group had 
not received the study drug for 48 weeks because 
of early toxicity, leaving three cases of resistant 
infection in the TDF–FTC group among partici-
pants who may have had access to the study drug 
around the time of acquiring the infection. Sero-
conversion was discovered in these three partici-
pants within 12 weeks after enrollment. Thus, 
despite intensive testing, we cannot definitively 
rule out the possibility that the participants were 
already infected at enrollment.
It has been suggested that the use of TDF–FTC 
may mask HIV infection by modifying the viral 
load and antibody production. However, the simi-
larity in the rates of HIV infection in the two study 
groups after study-drug discontinuation is not 
consistent with this concern.
Although we suspect that the lack of efficacy of 
TDF–FTC in our study population was due to low 
adherence, biologic factors may also be involved. 
The protective effect of TDF–FTC might be dimin-
ished in the presence of a very high viral load in 
the infecting partner, as occurs in the acute phase 
of HIV infection. Another possible reason for the 
lack of efficacy of TDF–FTC is a high cytokine 
Table 3. (Continued.)
Variable TDF–FTC (N = 1025) Placebo (N = 1033) P Value†
no. of participants no. of cells no. of participants no. of cells
Participants with seroconversion¶
CD4+ count
At first evidence of infection 11 14 0.16
Mean 443.5 602.9
Median 388 560
At seroconversion visit 31 31 0.44
Mean 561.2 613.5
Median 511 576
At 16 wk after seroconversion 26 21 0.94
Mean 579.3 586.5
Median 580 491
no. of participants log10 value no. of participants log10 value
Viral load
At first evidence of infection 33 35 0.61
Mean 4.9 5.1
Median 5.2 5.3
At seroconversion visit 32 35 0.92
Mean 5.2 5.2
Median 5.0 5.1
At 16 wk after seroconversion 27 22 0.70
Mean 4.4 4.3
Median 4.6 4.5
* Listed are adverse events for all participants to whom the study drug was provided, regardless of HIV infection status at enrollment as de-
termined by subsequent testing. ALT denotes alanine aminotransferase, and AST aspartate aminotransferase.
† P values are based on Fisher’s exact tests for adverse events, exact log-rank tests for primary safety end points, and t-tests for CD4+ cell 
counts and log10 viral loads.
‡ A complete list of serious adverse events is provided in Table S2 in the Supplementary Appendix.
§ This grade of abnormality was a prespecified primary safety end point.
¶ Data were missing for some participants with seroconversion because of a lack of stored blood specimens before seroconversion, partici-
pant refusal of additional blood tests, invalid test results, or missed visits.
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level. It has been reported that the effect of vagi-
nal tenofovir 1% gel may be lower in women with 
an elevated vaginal cytokine profile.13
Our trial has several limitations. The low ad-
herence impairs our ability to make clear conclu-
sions regarding the effectiveness and safety of 
TDF–FTC in the study population. In addition, 
13% of the participants were lost to follow-up. 
Although we were able to document that a third 
of these women had relocated outside the study 
area, the absence of HIV testing at the final visit 
means that we cannot rule out the possibility 
that a difference in rates of HIV acquisition ex-
isted between the two study groups among those 
who were lost to follow-up.
In conclusion, prophylaxis with TDF–FTC did 
not reduce the rate of HIV infection and was as-
sociated with increased rates of side effects, as 
compared with placebo. However, we were un-
able to accurately assess the effect of TDF–FTC on 
HIV acquisition or safety because of low study-
drug adherence, which may be an indication that 
a daily pill-taking regimen will be difficult for 
some populations. A better understanding of in-
dicators of adherence among women at high risk 
for HIV infection is needed to ensure the effec-
tiveness of future preexposure prophylaxis pro-
grams.
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